P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2019

Global Markets Direct’s, ‘P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2019’, provides in depth analysis on P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Immunology, Oncology, Genetic Disorders and Gastrointestinal under development targeting P2X Purinoceptor 7 (P2Z Receptor or P2RX7).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

  • Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)

- The report reviews P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics and enlists all their major and minor projects

- The report assesses P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 7 (P2Z Receptor or P2RX7) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Affectis Pharmaceuticals AG

Asahi Kasei Pharma Corp

Axxam SpA

Biosceptre International Ltd

Evotec SE

Integral Molecular Inc

Johnson & Johnson

Lead Discovery Center GmbH

MindImmune ...

Affectis Pharmaceuticals AG

Asahi Kasei Pharma Corp

Axxam SpA

Biosceptre International Ltd

Evotec SE

Integral Molecular Inc

Johnson & Johnson

Lead Discovery Center GmbH

MindImmune Therapeutics Inc

MyoTherix Inc

Suven Life Sciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Overview

P2X ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Overview

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Companies Involved in Therapeutics Development

Affectis Pharmaceuticals AG

Asahi Kasei Pharma Corp

Axxam SpA

Biosceptre International Ltd

Evotec SE

Integral Molecular Inc

Johnson & Johnson

Lead Discovery Center GmbH

MindImmune Therapeutics Inc

MyoTherix Inc

Suven Life Sciences Ltd

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Drug Profiles

AFC-5128 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AKP-23494954 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIL-010t - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIL-03s - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIL-06v - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIL-07v - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EVT-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-5446 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-55308942 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Antagonize P2X7 for Immunology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small molecule to Antagonize P2X7 for Multiple Sclerosis and Epilepsy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize P2X7 Receptor for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize P2RX7 for CNS Disorders, Autoimmune Disorders and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize P2X7 for Inflammation and Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize P2X7 for Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Dormant Products

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Discontinued Products

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Product Development Milestones

Featured News & Press Releases

Nov 14, 2018: Update on phase I trial of vaccine BIL06v

Aug 21, 2018: Initiation of Biosceptre’s phase 1 clinical trial for first-in-class oncology vaccine BIL06v

Mar 03, 2017: Biosceptre publishes a clinical study of topical drug BIL010t as therapy for Basal cell carcinoma

Dec 18, 2014: Alzheimer’s Drug Discovery Foundation And Axxam Continue Their Successful Collaboration To Develop Novel Therapeutics For Alzheimer’s Disease

Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma

Jan 25, 2012: Affectis Receives European Patent For AFC-5128 And Other P2X7 Antagonists

Jun 29, 2009: Evotec Announces The Successful Completion Of The First Phase I Study With EVT 401

Oct 09, 2008: Evotec Announces Phase I Initiation With P2X7 Antagonist

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number ...

List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Affectis Pharmaceuticals AG, H2 2019

Pipeline by Asahi Kasei Pharma Corp, H2 2019

Pipeline by Axxam SpA, H2 2019

Pipeline by Biosceptre International Ltd, H2 2019

Pipeline by Evotec SE, H2 2019

Pipeline by Integral Molecular Inc, H2 2019

Pipeline by Johnson & Johnson, H2 2019

Pipeline by Lead Discovery Center GmbH, H2 2019

Pipeline by MindImmune Therapeutics Inc, H2 2019

Pipeline by MyoTherix Inc, H2 2019

Pipeline by Suven Life Sciences Ltd, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number ...

List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports